LOTENSIN HCT (benazepril hydrochloride and hydrochlorothiazide) by Bausch Health is clinical pharmacology mechanism of action benazepril and benazeprilat inhibit angiotensin converting enzyme (ace) in human subjects and in animals. Approved for hypertension. First approved in 1992.
Drug data last refreshed 5h ago · AI intelligence enriched 1w ago
LOTENSIN HCT is a fixed-dose combination oral tablet containing benazepril hydrochloride (an ACE inhibitor) and hydrochlorothiazide (a thiazide diuretic) for the treatment of hypertension. It works by inhibiting angiotensin-converting enzyme to reduce angiotensin II-mediated vasoconstriction and by promoting sodium and chloride excretion to reduce plasma volume. The combination approach balances the potassium-elevating effect of ACE inhibition with the potassium-lowering effect of diuresis.
Product is approaching loss of exclusivity with minimal recent spending and low claims volume, indicating reduced commercial investment and team contraction likelihood.
CLINICAL PHARMACOLOGY Mechanism of Action Benazepril and benazeprilat inhibit angiotensin converting enzyme (ACE) in human subjects and in animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also…
Worked on LOTENSIN HCT at Bausch Health? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Thiazide Diuretic
Fed Study of Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Lotensin HCT® Tablets 20 mg/25 mg
Fasting Study of Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Lotensin HCT® Tablets 20 mg/25 mg
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moWith zero linked job openings and approaching LOE, career opportunities in LOTENSIN HCT are limited and focused on defending market share against newer competitors. Roles available are primarily tactical (pricing, contracting, sales retention) rather than strategic growth positions, making this a challenging career destination.